Elite Pharmaceuticals, Inc. (ELTP)
OTCMKTS: ELTP · Delayed Price · USD
0.130
0.00 (-0.14%)
May 1, 2024, 11:02 AM EDT - Market open
Elite Pharmaceuticals Revenue
Elite Pharmaceuticals had revenue of $47.32M in the twelve months ending December 31, 2023, with 42.61% growth year-over-year. Revenue in the quarter ending December 31, 2023 was $15.54M with 67.99% year-over-year growth. In the fiscal year ending March 31, 2023, Elite Pharmaceuticals had annual revenue of $34.16B with 105,767.55% growth.
Revenue (ttm)
$47.32M
Revenue Growth
+42.61%
P/S Ratio
2.79
Revenue / Employee
$892,785
Employees
53
Market Cap
131.80M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2023 | 34.16B | 34.12B | 105,767.55% |
Mar 31, 2022 | 32.26M | 6.88M | 27.11% |
Mar 31, 2021 | 25.38M | 7.39M | 41.05% |
Mar 31, 2020 | 17.99M | 10.43M | 137.76% |
Mar 31, 2019 | 7.57M | 109.80K | 1.47% |
Mar 31, 2018 | 7.46M | -2.18M | -22.61% |
Mar 31, 2017 | 9.64M | -2.86M | -22.89% |
Mar 31, 2016 | 12.50M | 7.48M | 149.21% |
Mar 31, 2015 | 5.02M | 413.87K | 8.99% |
Mar 31, 2014 | 4.60M | 1.20M | 35.19% |
Mar 31, 2013 | 3.40M | 979.41K | 40.40% |
Mar 31, 2012 | 2.42M | -1.84M | -43.18% |
Mar 31, 2011 | 4.27M | 921.67K | 27.56% |
Mar 31, 2010 | 3.34M | 1.07M | 47.01% |
Mar 31, 2009 | 2.27M | 861.71K | 60.98% |
Mar 31, 2008 | 1.41M | 269.28K | 23.54% |
Mar 31, 2007 | 1.14M | 593.14K | 107.71% |
Mar 31, 2006 | 550.70K | 249.22K | 82.66% |
Mar 31, 2005 | 301.48K | 43.23K | 16.74% |
Mar 31, 2004 | 258.25K | -372.06K | -59.03% |
Mar 31, 2003 | 630.31K | -567.20K | -47.36% |
Mar 31, 2002 | 1.20M | 1.10M | 1,157.28% |
Mar 31, 2001 | 95.25K | 84.93K | 823.37% |
Mar 31, 2000 | 10.32K | -189.69K | -94.84% |
Mar 31, 1999 | 200.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
ELTP News
- 2 months ago - Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information - Accesswire
- 2 months ago - Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024 - Accesswire
- 4 months ago - Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant - Accesswire
- 5 months ago - Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC - Accesswire
- 6 months ago - Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information - Accesswire
- 6 months ago - Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023 - Accesswire
- 7 months ago - Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product - Accesswire
- 8 months ago - Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer - Accesswire